CU24682B1 - Una composición de vacuna multivalente compuesta por una mezcla de antígenos provenientes de virus de polio y rotavirus inactivados - Google Patents
Una composición de vacuna multivalente compuesta por una mezcla de antígenos provenientes de virus de polio y rotavirus inactivadosInfo
- Publication number
- CU24682B1 CU24682B1 CU2019000013A CU20190013A CU24682B1 CU 24682 B1 CU24682 B1 CU 24682B1 CU 2019000013 A CU2019000013 A CU 2019000013A CU 20190013 A CU20190013 A CU 20190013A CU 24682 B1 CU24682 B1 CU 24682B1
- Authority
- CU
- Cuba
- Prior art keywords
- vaccine composition
- inactivated
- rotaviruses
- antigens
- mixture
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
<p>La presente invención se refiere a una composición de vacuna multivalente que comprende: i) antígeno de virus de polio inactivado (IPV) seleccionado entre la cepa Salk o Sabin; ii) antígeno de rotavirus inactivado (IRV) de la cepa CDC-9; iii) un adyuvante como hidróxido donde el antígeno del IPV es adsorbido en un adyuvante de hidróxido de aluminio con un porcentaje de adsorción del hidróxido de aluminio en un rango de 70-99%, donde el antígeno del rotavirus es una cepa del rotavirus CDC-9 inactivada por el calor y se adsorbe en un adyuvante que contiene hidróxido de aluminio, y la concentración del rotavirus inactivado es 10 µg/dosis cuando la composición de vacuna es bivalente y multivalente.</p>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201621029037 | 2016-08-26 | ||
PCT/IB2017/055100 WO2018037365A1 (en) | 2016-08-26 | 2017-08-24 | Multivalent vaccine composition |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20190013A7 CU20190013A7 (es) | 2019-10-04 |
CU24682B1 true CU24682B1 (es) | 2023-10-06 |
Family
ID=60083359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2019000013A CU24682B1 (es) | 2016-08-26 | 2017-08-24 | Una composición de vacuna multivalente compuesta por una mezcla de antígenos provenientes de virus de polio y rotavirus inactivados |
Country Status (17)
Country | Link |
---|---|
US (1) | US11235054B2 (es) |
EP (1) | EP3503917B1 (es) |
JP (3) | JP7384667B2 (es) |
KR (1) | KR102607295B1 (es) |
CN (1) | CN110691611A (es) |
AU (1) | AU2017316768B2 (es) |
BR (1) | BR112019003419A2 (es) |
CA (1) | CA3032901A1 (es) |
CU (1) | CU24682B1 (es) |
EA (1) | EA201900117A1 (es) |
IL (1) | IL264605B2 (es) |
MX (1) | MX2019001780A (es) |
MY (1) | MY191163A (es) |
PE (1) | PE20200004A1 (es) |
PH (1) | PH12019500404A1 (es) |
SG (1) | SG11201900365WA (es) |
WO (1) | WO2018037365A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201900365WA (en) * | 2016-08-26 | 2019-02-27 | Serum Institute Of India Pvt Ltd | Multivalent vaccine composition |
EP3621645A4 (en) * | 2017-05-10 | 2021-01-27 | University of Massachusetts | BIVALENT DENGUE / HEPATITIS B VACCINES |
JOP20190242A1 (ar) * | 2018-10-12 | 2020-04-12 | Serum Institute Of India Pvt Ltd | تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها |
JOP20200214A1 (ar) | 2019-09-03 | 2021-03-03 | Serum Institute Of India Pvt Ltd | تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006113528A2 (en) | 2005-04-18 | 2006-10-26 | Novartis Vaccines And Diagnostics Inc. | Expressing hepatitis b virus surface antigen for vaccine preparation |
MX2009002560A (es) * | 2006-09-07 | 2009-03-20 | Glaxosmithkline Biolog Sa | Vacuna. |
PE20100365A1 (es) * | 2008-10-24 | 2010-05-21 | Panacea Biotec Ltd | Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion |
CA3121471A1 (en) | 2009-05-12 | 2010-11-18 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention | New human rotavirus strains and vaccines |
EP3459562B1 (en) * | 2011-01-05 | 2024-03-20 | Bharat Biotech International Limited | A combination heptavalent vaccine |
US20140112950A1 (en) * | 2011-03-02 | 2014-04-24 | Manmohan Singh | Combination vaccines with lower doses of antigen and/or adjuvant |
HUE049104T2 (hu) * | 2014-10-07 | 2020-08-28 | Serum Institute Of India Pvt Ltd | Javított eljárások poliovírus inaktiválására, adjuváns adszorpciója |
SG11201900365WA (en) * | 2016-08-26 | 2019-02-27 | Serum Institute Of India Pvt Ltd | Multivalent vaccine composition |
-
2017
- 2017-08-24 SG SG11201900365WA patent/SG11201900365WA/en unknown
- 2017-08-24 AU AU2017316768A patent/AU2017316768B2/en active Active
- 2017-08-24 CU CU2019000013A patent/CU24682B1/es unknown
- 2017-08-24 BR BR112019003419-6A patent/BR112019003419A2/pt active Search and Examination
- 2017-08-24 US US16/327,513 patent/US11235054B2/en active Active
- 2017-08-24 EA EA201900117A patent/EA201900117A1/ru unknown
- 2017-08-24 KR KR1020197008377A patent/KR102607295B1/ko active IP Right Grant
- 2017-08-24 CN CN201780052380.5A patent/CN110691611A/zh active Pending
- 2017-08-24 MY MYPI2019001011A patent/MY191163A/en unknown
- 2017-08-24 IL IL264605A patent/IL264605B2/en unknown
- 2017-08-24 PE PE2019000409A patent/PE20200004A1/es unknown
- 2017-08-24 CA CA3032901A patent/CA3032901A1/en active Pending
- 2017-08-24 MX MX2019001780A patent/MX2019001780A/es unknown
- 2017-08-24 JP JP2019532214A patent/JP7384667B2/ja active Active
- 2017-08-24 EP EP17783992.5A patent/EP3503917B1/en active Active
- 2017-08-24 WO PCT/IB2017/055100 patent/WO2018037365A1/en active Search and Examination
-
2019
- 2019-02-26 PH PH12019500404A patent/PH12019500404A1/en unknown
-
2021
- 2021-07-16 JP JP2021118038A patent/JP2021181445A/ja active Pending
-
2023
- 2023-10-06 JP JP2023174503A patent/JP2024009899A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR102607295B1 (ko) | 2023-11-29 |
EP3503917B1 (en) | 2024-07-03 |
IL264605B2 (en) | 2023-04-01 |
IL264605B (en) | 2022-12-01 |
MY191163A (en) | 2022-06-03 |
SG11201900365WA (en) | 2019-02-27 |
WO2018037365A8 (en) | 2018-09-20 |
KR20190142311A (ko) | 2019-12-26 |
AU2017316768B2 (en) | 2024-04-11 |
CA3032901A1 (en) | 2018-03-01 |
US11235054B2 (en) | 2022-02-01 |
EP3503917A1 (en) | 2019-07-03 |
EA201900117A1 (ru) | 2019-09-30 |
PH12019500404A1 (en) | 2020-01-20 |
JP7384667B2 (ja) | 2023-11-21 |
MX2019001780A (es) | 2020-01-13 |
WO2018037365A1 (en) | 2018-03-01 |
JP2024009899A (ja) | 2024-01-23 |
JP2021181445A (ja) | 2021-11-25 |
PE20200004A1 (es) | 2020-01-06 |
CN110691611A (zh) | 2020-01-14 |
AU2017316768A1 (en) | 2019-04-11 |
US20190175722A1 (en) | 2019-06-13 |
CU20190013A7 (es) | 2019-10-04 |
IL264605A (en) | 2019-02-28 |
JP2019526635A (ja) | 2019-09-19 |
BR112019003419A2 (pt) | 2019-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU24682B1 (es) | Una composición de vacuna multivalente compuesta por una mezcla de antígenos provenientes de virus de polio y rotavirus inactivados | |
MX2020004543A (es) | Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan. | |
CO6551750A2 (es) | Vacuna del virus del dengue inactivado que incluye un adyuvante sin aluminio | |
MX2020005554A (es) | Vacunas y composiciones inmunogenas para zika y metodos para usarlas. | |
PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
WO2014150822A3 (en) | Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use | |
EA201892735A1 (ru) | Состав вакцины против hiv | |
CO7461131A2 (es) | Antígenos recombinantes del porcine circovirus 2 (pcv-2) para formulaciones de vacuna, kit de diagnóstico y uso | |
CO6440541A2 (es) | Virus de diarrea viral bovina con una proteina erns modificada | |
AR106026A1 (es) | Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos | |
AR080111A1 (es) | Metodos y composiciones de inmunizacion | |
EA201591663A1 (ru) | Бесклеточная противококлюшная вакцина | |
PH12018502436A1 (en) | Multivalent vaccines major swine viral diseases | |
AR108829A1 (es) | Vacuna contra virus de bronquitis infecciosa | |
PH12018501368A1 (en) | M hyo multivalent vaccine and uses thereof | |
PE20171132A1 (es) | Metodos mejorados para la inactivacion de enterovirus y la adsorcion sobre coadyuvantes, y composiciones de vacunas con dosis reducidas obtenidas de estos | |
CL2021003211A1 (es) | Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018) | |
CL2019003393A1 (es) | Virus oncolíticos y método. | |
WO2018066999A3 (en) | Chimeric enterovirus virus-like particles | |
AR089282A1 (es) | Poliovirus atenuado: pv-1 mono-cre-x | |
AR085800A1 (es) | Vacuna de rinitis equina | |
AR115070A1 (es) | Células madre que comprenden un virus vacuna quimérico sintético y métodos para su uso | |
CO2020011984A2 (es) | Cepa del virus de la fiebre amarilla viva atenuada adaptada para el crecimiento en células vero y composición de vacuna que la comprende | |
AR114410A1 (es) | Vacuna multivalente contra influenza viva atenuada para prevenir y controlar el virus influenza equino (vie) en caballos | |
BR112019008584A2 (pt) | vacinas de mosaico para vírus de doença de pé-e-boca de sorotipo a |